Employing PSI™ to summarize complex single-cell cytokine data

See how PSI corelates with objective response across cancer immunotherapies and is accelerating discovery and development.

Unlock Resource
Download this free resource and gain access to our full resource library!

Unlock All Resources

We will always keep your personal information safe. Complete this form to get unlimited access to all of our web resources and join over 10,000 leading researchers who receive industry pioneers' backed data straight to their inbox. By submitting this form, you agree to receive communications from IsoPlexis and accept our Privacy Policy.

You may unsubscribe and update your email subscription at any time.

fierce innovation award
red dot award winner
scientist award

Employing PSI™ to summarize complex single-cell cytokine data

IsoPlexis’ Polyfunctional Strength Index (PSI) is a powerful, novel metric for measuring the potency of a variety of immune cell types in cancer immunotherapy, based on the ability to uniquely isolate & detect potent functional cell subsets.

In this Tech Note we discuss:
  • Polyfunctionality alone is a meaningful indicator of potency in a variety of immunotherapy types, including CAR T therapy, where PSI has significantly outperformed other pre-infusion metrics.
  • Many researchers are also using sub-components of the PSI to develop a sub-component polyfunctional strength cell subset driver, such as IL-17 or Stimulatory driven Polyfunctional Strength.
  • The PSI Index reveals aggregate differences that guide your deep dive into polyfunctional cell subsets, via single-cell heat maps and cellular analyses like PAT PCA and t-SNE, that can reveal biomarkers and development insights.